Characterization of a novel series of potent, selective inhibitors of wild type and mutant/fusion anaplastic lymphoma kinase

被引：6
|
作者：
Wilcoxen, Keith M. [1 ]
Brake, Rachael L. [2 ]
Saffran, Doug [2 ]
Teffera, Yohannes [2 ]
Choguette, Deborah [2 ]
Whittington, Doug [2 ]
Yu, Violeta [2 ]
Romero, Karina [2 ]
Bode, Christiane [2 ]
Stellwagen, John [2 ]
Potashman, Michelle [2 ]
Emkey, Renee [2 ]
Andrews, Paul [2 ]
Drew, Allison E. [2 ]
Xu, Man [2 ]
Szilvassy, Stephen [3 ]
Al-Assad, Samer [3 ]
Lewis, Richard T. [2 ]
机构：
[1] Tesaro Inc, Waltham, MA USA
[2] Amgen Inc, Cambridge, MA USA
[3] Amgen Inc, Thousand Oaks, CA USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-1795
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1795
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening
    Shin, Saemina
    Mah, Shinmee
    Hong, Sungwoo
    Park, Hwangseo
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2016, 56 (04) : 802 - 810
  • [22] Synthesis and characterization of novel quinazoline type inhibitors for mutant and wild-type EGFR and RICK kinases
    Breza, Nora
    Pato, Janos
    Orfi, Laszlo
    Hegymegi-Barakonyi, Balint
    Banhegyi, Peter
    Varkondi, Edit
    Borbely, Gabor
    Petak, Istvan
    Keri, Gyoerg
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2008, 28 (04) : 361 - 373
  • [23] A novel series of potent and selective IKK2 inhibitors
    Bingham, AH
    Davenport, RJ
    Gowers, L
    Knight, RL
    Lowe, C
    Owen, DA
    Parry, DM
    Pitt, WR
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (02) : 409 - 412
  • [24] A novel series of potent and selective histone deacetylase inhibitors.
    Jones, Philip
    Altamura, Sergio
    Chakravarty, Prasun K.
    Ingenito, Raffaele
    Petrocchi, Alessia
    Rowley, Michael
    Scarpelli, Rita
    Serafini, Sergio
    Steinkuhler, Christian
    CANCER RESEARCH, 2006, 66 (08)
  • [25] Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitors
    Grimster, Neil P.
    Gingipalli, Lakshmaiah
    Balazs, Amber
    Barlaam, Bernard
    Boiko, Scott
    Boyd, Scott
    Dry, Hannah
    Goldberg, Frederick W.
    Ikeda, Tim
    Johnson, Tony
    Kawatkar, Sameer
    Kemmitt, Paul
    Lamont, Scott
    Lorthioir, Olivier
    Mfuh, Adelphe
    Patel, Joe
    Pike, Andy
    Read, Jon
    Romero, Romulo
    Sarkar, Ujjal
    Sha, Li
    Simpson, Iain
    Song, Kun
    Su, Qibin
    Wang, Haixia
    Watson, David
    Wu, Allan
    Zehnder, Troy E.
    Zheng, XiaoLan
    Li, Shaolu
    Dong, Zhiqiang
    Yang, Dejian
    Song, Yanwei
    Wang, Peng
    Liu, Xuemei
    Dowling, James E.
    Edmondson, Scott D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 91
  • [26] Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma
    Myint, Kyaw Zwar
    Sueca-Comes, Mireia
    Collier, Pamela
    Balasubramanian, Brinda
    Venkatraman, Simran
    Gordan, John
    Zaitoun, Abed M.
    Mukherjee, Abhik
    Arora, Arvind
    Larbcharoensub, Noppadol
    Suriyonplengsaeng, Chinnawut
    Wongprasert, Kanokpan
    Janvilisri, Tavan
    Gomez, Dhanny
    Grabowska, Anna M.
    Tohtong, Rutaiwan
    Bates, David O.
    Yacqub-Usman, Kiren
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [27] Indole-ether quinazolines:: A novel series of selective and potent VEGF receptor tyrosine kinase inhibitors
    Wedge, SR
    Hennequin, LF
    Ogilvie, DJ
    Kendrew, J
    Dukes, M
    Stokes, ESE
    McKerrecher, D
    Plé, P
    Curry, B
    BRITISH JOURNAL OF CANCER, 2001, 85 : 34 - 34
  • [28] Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor
    Cools, J
    Wlodarska, I
    Somers, R
    Mentens, N
    Pedeutour, F
    Maes, B
    De Wolf-Peeters, C
    Pauwels, P
    Hagemeijer, A
    Marynen, P
    GENES CHROMOSOMES & CANCER, 2002, 34 (04): : 354 - 362
  • [29] In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
    Sjin, Robert Tjin Tham
    Lee, Kwangho
    Walter, Annette O.
    Dubrovskiy, Aleksandr
    Sheets, Michael
    St Martin, Thia
    Labenski, Matthew T.
    Zhu, Zhendong
    Tester, Richland
    Karp, Russell
    Medikonda, Aravind
    Chaturvedi, Prasoon
    Ren, Yixuan
    Haringsma, Henry
    Etter, Jeff
    Raponi, Mitch
    Simmons, Andrew D.
    Harding, Thomas C.
    Niu, Deqiang
    Nacht, Mariana
    Westlin, William F.
    Petter, Russell C.
    Allen, Andrew
    Singh, Juswinder
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (06) : 1468 - 1479
  • [30] Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: Wild type and mutant (L1196M) active compounds with unique binding mode
    Gummadi, Venkateshwar Rao
    Rajagopalan, Sujatha
    Looi, Chung-Yeng
    Paydar, Mohammadjavad
    Renukappa, Girish Aggunda
    Ainan, Bharathi Raja
    Krishnamurthy, Narasimha Rao
    Panigrahi, Sunil Kumar
    Mahasweta, Kumari
    Raghuramachandran, Sangeetha
    Rajappa, Manoj
    Ramanathan, Anuradha
    Lakshminarasimhan, Anirudha
    Ramachandra, Murali
    Wong, Pooi-Fong
    Mustafa, Mohammad Rais
    Nanduri, Srinivas
    Hosahalli, Subramanya
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (17) : 4911 - 4918
12345